Wanbury Limited has announced the successful commencement of commercial production of a high-potent anaesthetic Active Pharmaceutical Ingredient (API) at its state-of-the-art manufacturing facility in Tanuku, Andhra Pradesh. The development marks a significant milestone in the company’s growth strategy and is expected to drive robust revenue momentum in Q4 FY26 and FY27.
The newly launched anaesthetic API is projected to generate incremental revenues of approximately ₹18 crore in the fourth quarter of FY26 alone, supported by rising global demand and Wanbury’s strong presence in regulated API markets. The commercial rollout further strengthens the company’s position in the domestic and international pharmaceutical supply chain.
In addition to this achievement, Wanbury is progressing rapidly on its upcoming multi-purpose intermediate production block at the Tanuku facility. The new block is scheduled to be commercially operational by the end of March 2026 and will significantly expand the company’s manufacturing capabilities.
Once operational, the facility will support the production of four high-value APIs across key therapeutic segments, including antidiabetic, anticoagulant (blood thinner), cough suppressant (anti-tussive), and antidepressant molecules. These products are collectively expected to generate revenues exceeding ₹100 crore for Wanbury in FY27, driven by strong export demand and growing global healthcare needs.
The global market size for these four APIs is currently estimated at over ₹5,000 crore, offering substantial long-term growth opportunities for the company as it continues to scale up capacity and diversify its API portfolio.
Commenting on the development, Mohan Rayana, Director of Wanbury Limited, said the expansion reinforces the company’s commitment to supplying high-quality, reliable APIs to global markets. He highlighted that the strategic investments at the Tanuku facility are aimed at strengthening Wanbury’s competitive position while addressing critical therapeutic demands worldwide.
